Join our daily newsletter At The Bell to receive exclusive market insights
- Nuheara (NUH) commences a clinical trial to test the safety and effectiveness of its newly developed range of hearing aid products
- This clinical trial aims to expand Nuheara’s hearing solutions around the globe
- To help with this trial, the company has engaged National Acoustics Laboratories, with Deborah Arthur leading Nuheara’s research team
- Nuheara is up 2.94 per cent, trading at 3.5 cents per share at 10:53 am AEST
Nuheara (NUH) will commence a clinical trial to test the safety and effectiveness of its newly developed range of hearing aid products.
This clinical trial aims to expand Nuheara’s hearing solutions around the globe by meeting requirements of the US Food and Drug Administration (FDA), the European Union and the Australian Therapeutic Goods Administration (TGA).
To help with this trial, the company has engaged National Acoustics Laboratories, with Deborah Arthur leading Nuheara’s research team.
Ms Arthur has been providing leadership over the past 30 years in the medical device industry especially for ear, nose and throat applications.
Commenting on the medical device clinical trial, Nuheara Co-founder and CEO, Justin Miller, said this clinical trial was the first step of the company’s evolution to a medical device company.
“Nuheara is well positioned for clinical trial success, with our Ear ID already clinically validated,” Mr Miller said. “We are a global pioneer in embedding the hearing aid prescription protocols into our range of IQbuds.
“A successful clinical trial will enable us to tackle any regulated hearing device market in the world, with our end-to-end range of affordable and accessible hearable and hearing aid devices.”
Nuheara was up 2.94 per cent, trading at 3.5 cents per share at 10:53 am AEST.
